A burdensome infection
In the US alone, staphylococcus aureus (SA) and methicillin resistant staphylococcus aureus (MRSA) infections burden the healthcare system with approximately $9.5 billion and $20 billion in annual care costs, respectively.1,2
Moreover, these staggering financial figures only capture a fraction of the burden attributed to MRSA and SA infections. Hospitalized patients endure prolonged stays and suffering, resulting in tangible and intangible costs that add to the considerable price tags associated with the increased morbidity and mortality rates due to MRSA/SA infections.
MRSA is a bacterial infection which causes the same infection as SA, however it is dangerous due to its resistance to many antibiotics that successfully treat normal SA. It is transmitted to an individual through bacterial contact with a wound, cut, or even ingrown hairs and razor burn on the skin’s surface. This transmission can come from the skin of another person with SA, or from a colonized environmental surface. When in the body it multiplies, invades host tissue, and causes severe inflammation and infection.3
It’s well established that SA is commonly found as part of the normal flora on the skin and in the respiratory tract of 30% of the population without negative effects on the carrier.4 However, up to 93% of hospital-acquired SA infections are caused by a patient’s own colonized flora.